18F-氟-2-脱氧-D-葡萄糖正电子发射断层-磁共振成像(18F-FDG PET-MRI)与18F-FDG PET-CT在头颈部鳞状细胞癌淋巴结评估中的临床评价
这项回顾性研究在常规临床诊疗中评估了18F-FDG PET-MRI与18F-FDG PET-CT对头颈部鳞状细胞癌淋巴结的评估准确性,共纳入256例患者(PET-MRI组130例,PET-CT组126例)。两种方法对恶性或良性淋巴结均显示高真阳性率和真阴性率(96-100%),PET-MRI和PET-CT判为可疑的淋巴结分别有18%和9%经病理证实为恶性。作者认为PET-MRI对可疑淋巴结的准确性略高,但诊断挑战仍存,并建议开展前瞻性临床试验。
要点
- 对判为恶性或良性的淋巴结,PET-MRI与PET-CT的真阳性率和真阴性率均达96-100%。
- PET-MRI判为可疑的淋巴结中18%经病理证实为恶性,PET-CT为9%。
- 作者认为PET-MRI对可疑淋巴结的准确性略高,但诊断挑战仍存。
核心结论
- 18F-FDG PET-MRI与PET-CT在识别恶性和良性淋巴结方面均表现出高准确性;PET-MRI对可疑淋巴结的准确性略高,但诊断挑战仍存。
研究设计与样本
- 回顾性研究,共纳入256例头颈部鳞状细胞癌患者,其中130例接受18F-FDG PET-MRI(平均年龄65±11岁,69%为男性),126例接受18F-FDG PET-CT(平均年龄68±10岁,69%为男性);采用专门的头颈部及全身协议采集;参考标准为病理结果、随访影像或多学科团队结论;分析包括病灶水平和患者水平。
诊断标准与关键数值
- 对判为恶性或良性的淋巴结,两种方法在病灶水平和患者水平分析中的真阳性率和真阴性率均为96-100%。
- PET-MRI判为可疑的淋巴结中18%经病理证实为恶性,PET-CT判为可疑的淋巴结中9%经病理证实为恶性。
临床应用与阅片要点
- 作者认为PET-MRI对可疑淋巴结的准确性略高,但诊断挑战仍存。
- 作者指出影像技术和疾病特异性示踪剂的进步可能改善头颈部鳞状细胞癌的淋巴结评估,并建议开展前瞻性临床试验,以减少对病理证实的依赖并缩短诊断延迟。
局限性
- 原文指出诊断挑战仍存。
- 原文结论提出需开展前瞻性临床试验,以减少对病理证实的依赖并缩短诊断延迟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: This retrospective study evaluated the accuracy of hybrid 2-[18F]fluoro-2-deoxy-d-glucose ([18F]FDG) positron emission tomography-magnetic resonance imaging (PET-MRI) and [18F]fluoro-2-deoxy-d-glucose positron emission tomography-computed tomography ([18F]FDG PET-CT) for lymph node assessment in patients with head and neck squamous cell carcinoma (HNSCC) within routine clinical care.
MATERIALS AND METHODS: Patients with HNSCC underwent either [18F]FDG PET-MRI or [18F]FDG PET-CT following a dedicated head and neck and whole-body protocol. Data on lymph nodes, both individually and pooled by ipsilateral and contralateral sides, were extracted from [18F]FDG PET-MRI/-CT reports. Lymph nodes and sides were categorised as malignant, suspicious, or benign. As a reference standard, results from pathology, follow-up imaging, or the conclusion established by a multidisciplinary team were used. Both lesion-wise and patient-wise analyses were performed.
RESULTS: A total of 256 patients were included: 130 underwent [18F]FDG PET-MRI (mean age 65 ± 11, 69% male) and 126 underwent [18F]FDG PET-CT (mean age 68 ± 10, 69% male). For lymph nodes classified as malignant or benign, both modalities showed high true-positive and negative rates (96-100%) in both lesion- and patient-wise analyses. Lymph nodes deemed suspicious on [18F]FDG PET-MRI and [18F]FDG PET-CT were pathologically confirmed as malignant in 18% and 9% of cases, respectively.
CONCLUSION: [18F]FDG PET-MRI/-CT demonstrate high accuracy in identifying malignant and benign lymph nodes. [18F]FDG PET-MRI shows slightly higher accuracy for suspicious lymph nodes, although diagnostic challenges remain. Advancements in imaging techniques and disease-specific tracers may improve lymph node evaluation in HNSCC, warranting prospective clinical trials to ultimately reduce reliance on pathological confirmation and minimise diagnostic delays.
引用
- Droogers E, Pruis IJ, van der Eerden AW, et al. Clinical evaluation of [18F]fluoro-2-deoxy-d-glucose positron emission tomography-magnetic resonance imaging ([18F]FDG PET-MRI) and [18F]FDG PET-computed tomography ([18F]FDG PET-CT) for lymph node assessment in head and neck squamous cell carcinoma. Clin Radiol. 2025. PMID: 41076945. doi:10.1016/j.crad.2025.107095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。